Pfizer prohibited from subsidizing its heart drugs for Medicare patients

A district judge ruled Sept. 30 that Pfizer cannot directly or indirectly pay out-of-pocket costs for Medicare patients to receive its heart drugs Vyndaqel and Vyndamax, which cost $225,000 annually.